Genocea Biosciences Inc. buy fchar99
Summary
This prediction ended on 10.12.18 with a price of €4.42. The prediction for Genocea Biosciences Inc. disappointed with a performance of -23.36%. fchar99 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | 1,93 % | -2,11 % | 11,14 % | 59,64 % |
| iShares Nasdaq 100 | -0,18 % | -5,90 % | -0,15 % | 82,45 % |
| iShares Nikkei 225® | 7,08 % | 6,46 % | 28,83 % | 59,33 % |
| iShares S&P 500 | -0,20 % | -3,67 % | -0,10 % | 55,65 % |
Comments by fchar99 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
fchar99 agrees with Mori8's Buy-prediction
On 10/09/2018, fchar99 agrees with Mori8's' Buy-prediction with a target price of €0.88.
Title: Mori8 stimmt der Buy-Einschätzung von Quitte zu